Press coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.4368652871104 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Notable Stocks to Keep Your Eyes on: Intercept Pharmaceuticals … – Stocks In The News (press release) (tradingnewsnow.com)
- NASH Stocks Brace For Shockwaves From Galectin Therapeutics Trial Results – Seeking Alpha (seekingalpha.com)
- Intercept Pharmaceuticals (ICPT) Upgraded to Sell at ValuEngine (americanbankingnews.com)
- Intercept Pharmaceuticals, Inc. Forecasted to Earn FY2017 Earnings of ($13.14) Per Share (ICPT) (americanbankingnews.com)
- Lookout for Price Target?: Bazaarvoice, Inc., (NASDAQ: BV), Intercept Pharmaceuticals, Inc., (NASDAQ: ICPT … – Stocks In The News (press release) (tradingnewsnow.com)
Several brokerages have recently weighed in on ICPT. Seaport Global Securities restated a “buy” rating and issued a $136.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, October 6th. JMP Securities restated an “outperform” rating and issued a $140.00 price objective (down previously from $150.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. BMO Capital Markets restated an “outperform” rating and issued a $221.00 price objective on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Oppenheimer restated an “outperform” rating and issued a $200.00 price objective on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. Finally, Jefferies Group restated a “buy” rating and issued a $275.00 price objective on shares of Intercept Pharmaceuticals in a report on Wednesday, September 20th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $144.13.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. During the same period in the prior year, the firm posted ($3.59) EPS. The business’s revenue was up 697.9% compared to the same quarter last year. sell-side analysts anticipate that Intercept Pharmaceuticals will post -13.35 earnings per share for the current year.
In other news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders sold 2,566 shares of company stock worth $151,025. Insiders own 4.50% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.